NCT06145308 2026-04-02
Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing
Peking Union Medical College
Phase 2 Recruiting
Clinical Trials
21 trialsNCT07472140 2026-03-16
PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer
N.N. Alexandrov National Cancer Centre
Phase 2/3 Recruiting
NCT06502691 2026-03-02
[18F]FTT Positron Emission Tomography for the Measurement of PARP Tumor Expression in Patients With Metastatic Breast Cancer
University of Washington
Phase 1/2 Recruiting
NCT07268794 2025-12-08
CONVERT-HB1
Fudan University
Phase 2 Not yet recruiting
NCT05200260 2025-02-10
Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer
Shanghai Gynecologic Oncology Group
Phase 2 Recruiting
NCT04584008 2024-10-15
VISIONARY
Peking University
Phase NA Active not recruiting
NCT01311713 2024-01-30
Study to Determine the Maximum Tolerated Dose of the PARP Inhibitor CEP-9722 in Participants With Solid Tumors
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 1/2 Terminated
NCT06121557 2023-11-08
Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 1 Recruiting
NCT04724031 2023-03-14
Real World Data Analysis of PARP Inhibitors Use in Patients With Ovarian Cancer
Hellenic Cooperative Oncology Group
Unknown
NCT03182673 2022-09-01
The Study of SHR7390 in Combination With SHR-1210 and SHR3162 in Patients With Advanced Solid Tumors
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Terminated
NCT05406999 2022-08-16
Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2 Recruiting
NCT05392686 2022-05-26
PD1 and PARP for Maintenance Therapy in NSLLC
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT04774627 2021-09-23
Pancytopenia Related to PARP Inhibitors (PancytoRIB)
University Hospital, Caen
Completed
NCT05044091 2021-09-14
HOPEI
Jiangsu Cancer Institute & Hospital
Unknown
NCT03951415 2021-04-01
DOMEC
Leiden University Medical Center
Phase 2 Unknown
NCT04326023 2021-03-11
Myelodysplastic Syndrome and Acute Myeloid Leukemia Related to PARP Inhibitors (MyeloRIB)
University Hospital, Caen
Completed
NCT03227016 2021-01-27
Study in Patients With SCLC of Veliparib in Combination With Topotecan
Central European Society for Anticancer Drug Research
Phase 1 Unknown
NCT04582552 2021-01-20
ROMP
Jiangsu Cancer Institute & Hospital
Unknown
NCT01033123 2016-03-17
A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Sensitive Recurrent Ovarian Cancer
Sanofi
Phase 2 Completed
NCT01033292 2016-03-17
A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Resistant Recurrent Ovarian Cancer
Sanofi
Phase 2 Completed
NCT02396433 2015-08-25
Combination of Carboplatin, Eribulin Mesylate, and E7449 in BRCA-Related Cancers
The University of Texas Health Science Center at San Antonio
Phase 1/2 Withdrawn